Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)

BACKGROUND The efficacy of antihypertensive drugs newer than diuretics and beta-blockers has not been established. We compared the effects of the calcium-channel blocker nifedipine once daily with the diuretic combination co-amilozide on cardiovascular mortality and morbidity in high-risk patients with hypertension. METHODS We did a prospective, randomised, double-blind trial in Europe and Israel in 6321 patients aged 55-80 years with hypertension (blood pressure > or = 150/95 mm Hg, or > or = 160 mm Hg systolic). Patients had at least one additional cardiovascular risk factor. We randomly assigned patients nifedipine 30 mg in a long-acting gastrointestinal-transport-system (GITS) formulation (n=3157), or co-amilozide (hydrochlorothiazide 25 mg [corrected] plus amiloride 2.5 mg; n=3164). Dose titration was by dose doubling, and addition of atenolol 25-50 mg or enalapril 5-10 mg. The primary outcome was cardiovascular death, myocardial infarction, heart failure, or stroke. Analysis was done by intention to treat. FINDINGS Primary outcomes occurred in 200 (6.3%) patients in the nifedipine group and in 182 (5.8%) in the co-amilozide group (18.2 vs 16.5 events per 1000 patient-years; relative risk 1.10 [95% CI 0.91-1.34], p=0.35). Overall mean blood pressure fell from 173/99 mm Hg (SD 14/8) to 138/82 mm Hg (12/7). There was an 8% excess of withdrawals from the nifedipine group because of peripheral oedema (725 vs 518, p<0.0001), but serious adverse events were more frequent in the co-amilozide group (880 vs 796, p=0.02). Deaths were mainly non-vascular (nifedipine 176 vs co-amilozide 172; p=0.81). 80% of the primary events occurred in patients receiving randomised treatment (157 nifedipine, 147 co-amilozide, difference 0.33% [-0.7 to 1.4]). INTERPRETATION Nifedipine once daily and co-amilozide were equally effective in preventing overall cardiovascular or cerebrovascular complications. The choice of drug can be decided by tolerability and blood-pressure response rather than long-term safety or efficacy.

[1]  C. Palmer,et al.  Influence of diabetes and type of hypertension on response to antihypertensive treatment. , 2000, Hypertension.

[2]  B. Psaty,et al.  Diuretic therapy for hypertension and the risk of primary cardiac arrest. , 1994, The New England journal of medicine.

[3]  Mj Brown,et al.  CAPPP trial , 1999, The Lancet.

[4]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[5]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[6]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[7]  G. Mancia,et al.  INSIGHT: international nifedipine GITS study intervention as a goal in hypertension treatment. , 1996, Journal of human hypertension.

[8]  L. Ferrucci,et al.  Calcium-channel blockade and incidence of cancer in aged populations , 1996, The Lancet.

[9]  R. Collins,et al.  Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. , 1994, British medical bulletin.

[10]  A. Dobson,et al.  Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations , 2000, The Lancet.

[11]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[12]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[13]  What does STOP-2 tell us about management of hypertension? , 2000, The Lancet.

[14]  J. Guralnik,et al.  Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old , 1996, The Lancet.

[15]  Bruce Neal,et al.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. , 1999, Journal of hypertension.

[16]  J. Guralnik,et al.  Long‐Term Survival and Use of Antihypertensive Medications in Older Persons , 1995, Journal of the American Geriatrics Society.

[17]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[18]  B Neal,et al.  1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. , 1999, Clinical and experimental hypertension.

[19]  L. Poston,et al.  British Hypertension Society guidelines for hypertension management 1999: summary , 1999, BMJ.

[20]  J A Staessen,et al.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension , 1998, Journal of hypertension.

[21]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[22]  P. Hamet,et al.  Shanghai trial of nifedipine in the elderly (STONE). , 1996, Journal of hypertension.

[23]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[24]  Detection.  The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[25]  S. MacMahon,et al.  An overview of 37 randomised trials of blood pressure lowering agents among 270,000 individuals. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. , 1999, Clinical and experimental hypertension.

[26]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[27]  G. Mancia,et al.  Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). , 1998, Journal of hypertension.

[28]  H. Tunstall-Pedoe,et al.  Changes in estimated coronary risk in the 1980s: data from 38 populations in the WHO MONICA Project. World Health Organization. Monitoring trends and determinants in cardiovascular diseases. , 1998, Annals of medicine.

[29]  T. Treasure,et al.  Minimisation: the platinum standard for trials? , 1998, BMJ.

[30]  M. J. Ashby,et al.  Optimisation of antihypertensive treatment by crossover rotation of four major classes , 1999, The Lancet.